Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Triclabendazole, Levamisole hydrochloride
Elanco Europe Ltd
QP52AC30
Triclabendazole, Levamisole hydrochloride
8.75 percent weight/volume
Oral suspension
LM: Licensed Merchant as defined in relevant national legislation
Sheep
combinations of benzimidazoles and related substances
Endoparasiticide
Authorised
2016-10-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Endex 8.75 % w/v Oral Suspension for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Oral suspension. A white to off-white aqueous suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the simultaneous treatment and control of mature and immature infections, including inhibited stages of stomach worms (_Haemonchus, Ostertagia, Trichostrongylus axei_), gut worms (_Trichostrongylus, Cooperia, Nematodirus,_ _Busonstomum, Gaigeria, Chabertia, Oesophagostomum_) and lung worms (_Dictyocaulus)_ as well as all forms of liver fluke infection (early immature, immature and adult stages of_ Fasciola hepatica and Fasciola gigantica_ susceptible to triclabendazole). For the treatment and control of nematodes resistant to benzimidazoles and probenzimidazoles, macrolide anthelmintics (e.g. ivermectin), salicylanides and tetrahydropyrimidines. 4.3 CONTRAINDICATIONS Do not administer to animals with known hypersensitivity to the active ingredients. Do not administer to goats. Active Substances Triclabendazole 5.0 % w/v Levamisole hydrochloride 3.75 % w/v Excipients Methyl parahydroxybenzoate (E218) 0.095 % w/v Propyl parahydroxybenzoate (E216) 0.035 % w/v Benzoic acid (E210) 0.1 % w/v Sodium metabisulphite (E223) 0.25 % w/v For a full list of excipients, see section 6.1 H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _1_ _/_ _1_ _0 Read the complete document